Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?

Ece Onur; Adnan Taner Kurdal; Berrin Tugrul; Ihsan Iskesen; Pınar Dundar; Fatma Taneli; Cevval Ulman; Ahmet Var

doi:10.1159/000333394

Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?

Med Princ Pract. 2012;21(2):160-3. doi: 10.1159/000333394. Epub 2011 Nov 5.

Authors

Ece Onur¹, Adnan Taner Kurdal, Berrin Tugrul, Ihsan Iskesen, Pınar Dundar, Fatma Taneli, Cevval Ulman, Ahmet Var

Affiliation

¹ Department of Biochemistry, Celal Bayar University School of Medicine, Manisa, Turkey.

PMID: 22067726
DOI: 10.1159/000333394

Abstract

Objective: To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, β-ﬁbrinogen -455 G → A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients.

Subjects and methods: Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups.

Results: Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk.

Conclusion: There is no possible benefit from genetic screening tests regarding VTE in cancer patients.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Disease Susceptibility
Female
Genetic Testing*
Humans
Male
Middle Aged
Neoplasms / complications*
Polymorphism, Genetic*
Venous Thromboembolism / complications
Venous Thromboembolism / genetics*